Mohammed Rassool

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · New England Journal of Medicine · 2022 · 352 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial

Ian Sanne, Catherine Orrell, Matthew P. Fox et al. · The Lancet · 2010 · 252 citations

Public Health, Advanced Practice Nursing, Clinical Pharmacy +13

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Conor Tweed, Rodney Dawson, Divan A. Burger et al. · The Lancet Respiratory Medicine · 2019 · 147 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +15

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Ruth Goodall, Sarah Meredith, Andrew Nunn et al. · The Lancet · 2022 · 145 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +11

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Robert S. Wallis, Sibuse Ginindza, Trevor Beattie et al. · The Lancet Respiratory Medicine · 2021 · 131 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13